Successfully completed a series of important financing rounds one after another

At the beginning of the new year, the biomedical industry in Nanjing Gulou District witnessed a series of encouraging news. Two representative enterprises in the area – Nanjing Hanxing Information Technology Co., Ltd. and Jiangsu Chuangyuan Life Science Technology Co., Ltd. – recently completed another round of significant financing, demonstrating strong innovation vitality and market recognition under different development models. This has set a good foundation for the development of the industry throughout the year.

Among them, Nanjing Hanxing Information Technology Co., Ltd. is a leading pet medical supply chain service platform in China, with its business covering nearly 50,000 pet medical service outlets across the country.

In recent years, the development of the enterprise has been steadily improving. The core B2B platform “Veterinarian’s First Choice” and the own brand “Beisibei Jian” have achieved large-scale layout in the pet medicine market, and their business scope is gradually expanding to overseas markets such as Southeast Asia.

The company has recently successfully completed the B+ round of financing, with investors including listed companies on the main board. This round of financing will significantly facilitate the construction of its own brand production lines and market expansion, providing solid support for the company to reach higher-level capital market goals.

Jiangsu Chuangyuan Life Technology Co., Ltd. is a prime example of the “school-city-enterprise-financial” deep integration model in Gulou District. As a hard-tech enterprise jointly incubated by Gulou District and China Pharmaceutical University on an innovation and transformation platform, it focuses on the research and development of therapeutic mRNA drugs for hepatitis B. Recently, it successfully completed a financing of over 60 million yuan.

This fund will be exclusively used to accelerate the global clinical trial application process for its first new drug, fully demonstrating the effectiveness of the precise transformation path of “original research by universities – platform incubation – capital empowerment”.
The continuous favor shown by capital is a reflection of the strength of innovative enterprises, and it is also a “vote” for the systematic innovation ecosystem of a region. In recent years, Gulou District has made systematic planning and in-depth efforts, activating university resources through the “one university, one specialty, one unique feature, one park” mechanism, and has formed an “innovation matrix” covering multiple fields such as digital, health, and green. The Jiangsu Chuangyuan Life that completed this financing is a vivid illustration of this matrix on the health economy track.

This is the “rich deposit” with the densest concentration of innovative resources.

Seven medical and pharmaceutical universities, 11 drug clinical trial institutions, and 12 tertiary hospitals are highly concentrated here, forming the shortest path from the discovery of target points at the source to clinical verification for biomedical innovation.

Here is the most professional platform for school-community cooperation and education.

In the field of health economy, Gulou District has jointly established the Brain-Computer Interface Research Institute with Nanjing University and Gulou Hospital, the Intelligent Biomanufacturing Innovation Center with Nanjing Normal University, and the Translational Medicine Research Institute with China Pharmaceutical University. These collaborations have created a solid “staircase” for bringing cutting-edge technologies from the laboratory to the market.

Here, a sequential capital empowerment system has been established.

To break through the capital chain link of “research – transformation – industry”, Gulou District is accelerating the construction of a relay-style financial network covering the entire life cycle of the project, connecting the entire process from “seedling planting” to “harvesting” of innovation. In the early concept verification stage of the project, Gulou District focused on introducing and investing in the Nanjing Biomedical Concept Verification Fund with a total scale of 300 million yuan. This fund actively selects high-quality early-stage projects across the country, and its first investment precisely landed in Gulou – it was invested in Jiangsu Chuangyuan Life Science Technology Co., Ltd., effectively solving the early financing problem of “from 0 to 0.5” in original innovation, and verifying an efficient path for the transformation of the results at this stage. To strengthen the ability to undertake local scientific research achievements, Gulou District is jointly building a complete fund support chain covering all stages from “concept verification – research and transformation – industrial expansion” with China Pharmaceutical University, Minmetals Securities, etc., to precisely match capital water for innovative projects at different stages.

Here you will find the most suitable carriers and precise services.

A number of specialized facilities such as the Huandao Pharmaceutical Industry Cluster Zone, the Brain-Computer Intelligence Science and Technology Park, and the Mufo Intelligent Valley Biotechnology Innovation Park have provided enterprises with “packaged and ready” research and development spaces. The series of brand activities launched by Gulou District, such as “Medical Sounds of Gulou”, offer one-stop services for the pharmaceutical industry, ranging from technology connection to financing introduction.

Under the dual nourishment of its unique resource endowment and comprehensive, targeted services, the life and health industry in Gulou District has begun to show notable results. On one hand, leading local enterprises such as Lingtong Pharmaceutical and Niubang Biotech have demonstrated strong growth momentum, driving the continuous expansion of the overall industrial scale. In 2025, the revenue of large-scale enterprises in the life and health sector within the district achieved rapid double-digit growth. On the other hand, a series of high-quality projects, including JD Health and Jicui Siji Kexin, have been attracted to the area, further strengthening the industrial chain, filling critical gaps, and extending industrial value, thereby injecting new momentum and vitality into the regional life and health industry.

The recent financing breakthroughs achieved by these two enterprises represent not only a critical step in their own development but also a phased achievement in Gulou District’s systematic efforts to build an industrial ecosystem. These breakthroughs offer vivid practical support for exploring efficient models to transform educational and scientific resources in urban areas, centered on the “Nanjing Biopharmaceutical R&D and Transformation Center.” Moving forward, Gulou District will continue to leverage its inherent strengths, promote the implementation of more university-industry collaboration outcomes, and enable more outstanding laboratory achievements—nourished by the precise infusion of financial resources—to steadily progress from the budding stage of technology to the formative stage of industry. This will contribute consistently to Nanjing’s vision of establishing itself as a global hub for biopharmaceutical innovation.